SecProbe.io

<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
                         [LETTERHEAD OF MILLENIA HOPE]

September 29, 2005

UNITED STATES
SECURITIES AND EXCHANGES COMMISSION
450 Fifth Street, N.W.
Washington, D.C. 20549

ATTENTION
Jim Peklenk, Staff Accountant
Division of Corporation Finance
Telephone Number: (202) 551 3661
Telecopier Number (202) 772 9217

Registrant: Millenia Hope, Inc.

Document:     Form 10-KSB for the Fiscal Year ended November 30, 2004
File Number:  000-29385

Dear Sirs,

In response to your letter of September 8, 2005:

Item 6

1. We will amend the discussion to read as follows:

On May 31, 2001, Millenia Hope and Liquid Asset Corp. signed a purchase
agreement, the terms of which gave Millenia the exclusive worldwide rights to
oxygenate intravenous solutions until September 1, 2005 with an option to
purchase these same rights for a further 5 year period. The purchase price for
these rights to September 1, 2005 was $500,000, 6 million Millenia Hope common
shares and 2 million non-registered common shares of Sword Comp-Soft Corp. that
were owned by Millenia.

As of Sept. 1,2005 Millenia did not exercise its option to purchase these rights
for another 5 years. At this time the company feels that it can better use its
resources to concentrate on its core business, infectious diseases especially
malaria. As the company is not currently actively engaged in this project, not
exercising its option will not have any impact on our business plan for 2005.

2.We will revise the Cibecol discussion as follows:

In 2001 Millenia acquired a 68% share of the assets of Cibecol Industrial
Farmaceutica Ltda. for $500,000,7 million shares of Millenia Hope common stock
and 1million common shares of Sword Comp-Soft Corp. As per the agreement between
the parties, these assets, of which a 68% share was purchased, were supposed to
be transferred into a newly formed corporation, to be owned 68% by Millenia and
32% by Cibecol, by Oct. 2002. This has not occurred and Millenia has written
down its investment to $1. Millenia had expected the transfer to be done by that
date, but the assets were never transferred from Cibecol to any other entity.
Currently, Millenia is not pursuing any legal course of action. After discussion
with its corporate counsel, it has been decided that, at this time, any legal
action to effect the transfer would require too much time and scarce resources
and is not in the company's best interest, at this time. Millenia could avail
itself of legal remedies and pursue the matter at a future date, if it judges
the action to be in the best interest of the Company, at that juncture.

Millenia continues to have regular commercial access to purchase Voacamine
processed by Cibecol and other producers in Southern Brazil and does not foresee
any supply shortages in the near future. Even though Millenia

<PAGE>

does not have exclusive access to Cibecol's Voacamine, due to the aforesaid, it
is still able to purchase Voacamine commercially from Cibecol and other
producers in the Region to satisfy its needs.

3. We will revise our discussion as follows:

The business objectives of Millenia are twofold. First and foremost is to
establish MMH(TM) Malarex/MMH(TM)18 as an accepted control agent for the
treatment and prevention of malaria throughout the world. We believe that
MMH(TM) Malarex/MMH(TM)18 is a highly effective anti-malarial drug, and will be
made available at prices that are competitive for a new anti-malarial agent with
no parasitic resistance. The availability and pricing of MMH(TM)
Malarex/MMH(TM)18, we believe, will ensure its acceptability and use in the
fight against malaria. To this end the company is involved in ongoing clinical
trials of MMH(TM) Malarex/MMH(TM)18. These trials, monitored by regional offices
of the World Health Organization (WHO) are designed to get MMH(TM)
Malarex/MMH(TM)18 global recognition as an anti-malarial treatment and allow
organizations, such as the Global Fund and other international Non-Governmental
Agencies (NGO), to fund the purchase of our products on behalf of countries.

Taking the aforementioned into account, as of August 31, 2005, Millenia Hope had
received 18 sales authorizations from West African nations, Congo (Brazzaville)
and Guinea (Conakry), Togo, Burundi, Central African Republic, Benin, Gabon,
Chad, Niger, Mali, Senegal, Democratic Republic of Congo, Guinea (Equatorial),
Cameroon, Ghana, Sierra Leone, Mauritania and Burkina Faso and one from the
Caribbean nation of the Dominican Republic. These authorizations mean that we
have the right currently, without doing any further testing or receiving any
further approval, to sell MMH Malarex(TM) to any individual, group, company or
NGO or Governmental Agency in those countries. In fact, as of September 2005
Millenia had 2 MMH Malarex sales, one in Guinea Conakry and one in Mali. We are
actively working with other groups and individuals to conclude further sales of
MMH(TM) Malarex/MMH(TM)18 . The only cost to concluding future sales is the
normal day to day operating costs of our business. We are awaiting sales
authorizations from several other African nations. Based on management's best
estimates, Millenia hopes to sell in excess of 300,000 treatments of MMH(TM)
Malarex/MMH(TM)18, in at least 2 major markets(or $3 million US), by the end of
fiscal 2005.

Millenia has adopted an extremely conservative sales forecast. In the face of
anti-malarial drug resistance, the need for effective treatments will continue
to intensify. Millenia has commenced building a network of local distributors
capable of supplying MMH(TM) Malarex/MMH(TM)18 and expects that the demand for
MMH(TM) Malarex/MMH(TM)18 to increase commensurately.

It is estimated that as the demand for MMH(TM) Malarex/MMH(TM)18 increases it
will become one of the accepted choices in the fight against malaria. Millenia
has chosen to remain conservative and has established a goal of capturing 1 1/2%
- 2% ($150 - $200 million) of the marketplace in five years, from the
commencement of its initial sales. According to the company's internal
estimates, based upon it's knowledge of the industry, attaining this sales level
will ensure the viability and profitability of the company for its shareholders.
No assurance can be given that the company will meet its sales goals.

Financial Statement - November 30, 2004

4. We have asked our auditors to remove the word "auditing" from their reports

5. We have asked our auditors to include a report that addresses the earlier
periods, from inception to November 30, 2004.

6.Non-controlling interest was the minority held portion of a former subsidiary
company of Millenia, namely Sword Comp-Soft Corp. Millenia divested its holding
in 2003 and the Company inadvertently classified those amounts in G&A and
disposal of sub, in the inception to date information, and will reclassify.

<PAGE>

7. We will revise the Statement of Operations to indicate the Research and
Development expenses and allocate other expenses, now included in Stock
Compensation expense, to their appropriate operating expense captions, as per
SFAS2, paragraph 13. Our MD+A section already breaks down all expenditures by
their appropriate operating expense captions and not as the category of "Stock
Compensation expense".

Should these revisions clarify matters, and are acceptable to the Securities and
Exchange Commission, we will amend our 10K-SB for year November 30, 2004 to
reflect those changes.

Millenia Hope acknowledges that:

      o     The company is responsible for the adequacy and accuracy of the
            disclosure in the filings;

      o     Staff comments or changes to disclosure in response to staff
            comments do not foreclose the commission from taking any action with
            respect to the filing; and

      o     The company may not assert staff comments as a defense in any
            proceeding initiated by the commission or any person under the
            federal securities laws of the United States.

Please be advised that Dr. Alexander Kavic has resigned his position as the
Vice-Chairman of Millenia Hope Inc, as per the June 2005 8-K filing, and that
the COO and a director of Millenia Hope, Mr. Yehuda Kops, will be corresponding
on behalf of the Company.

Sincerely

/s/ Yehuda Kops

YEHUDA KOPS
Chief Operating Officer
Millenia Hope Inc.
</TEXT>
</DOCUMENT>